Sarepta Therapeutics, Inc. $SRPT Stock Acquired by Virtus Advisers LLC

Virtus Advisers LLC grew its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 114.9% during the 3rd quarter, Holdings Channel.com reports. The fund owned 58,244 shares of the biotechnology company’s stock after acquiring an additional 31,146 shares during the period. Virtus Advisers LLC’s holdings in Sarepta Therapeutics were worth $1,061,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in SRPT. BlackRock Inc. purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth about $341,339,000. First Trust Advisors LP raised its stake in Sarepta Therapeutics by 107.6% during the 1st quarter. First Trust Advisors LP now owns 4,135,788 shares of the biotechnology company’s stock valued at $89,995,000 after purchasing an additional 2,143,211 shares during the period. Bank of America Corp DE bought a new stake in Sarepta Therapeutics during the 2nd quarter valued at approximately $36,946,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Sarepta Therapeutics in the 2nd quarter worth approximately $17,494,000. Finally, Legal & General Group Plc purchased a new position in Sarepta Therapeutics in the 2nd quarter worth approximately $15,771,000. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Price Performance

Shares of Sarepta Therapeutics stock traded up $0.06 during trading on Friday, reaching $16.07. 1,324,817 shares of the stock traded hands, compared to its average volume of 2,306,892. The business has a fifty day simple moving average of $18.59 and a two-hundred day simple moving average of $18.51. Sarepta Therapeutics, Inc. has a 52-week low of $14.68 and a 52-week high of $24.68. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.46 and a quick ratio of 2.13. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -11.73, a P/E/G ratio of 0.38 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. Sarepta Therapeutics had a negative net margin of 5.86% and a negative return on equity of 0.20%. The company had revenue of $381.35 million for the quarter, compared to the consensus estimate of $352.20 million. During the same quarter in the prior year, the firm earned ($0.13) earnings per share. Sarepta Therapeutics’s revenue was down 4.5% on a year-over-year basis. Sell-side analysts expect that Sarepta Therapeutics, Inc. will post 3.27 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (e+)” rating to a “sell (d)” rating in a research note on Thursday. Deutsche Bank upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating and lifted their price objective for the company from $14.00 to $18.00 in a research report on Tuesday, November 10th. Robert W. Baird set a $18.00 target price on shares of Sarepta Therapeutics in a report on Friday, November 6th. Royal Bank Of Canada boosted their target price on shares of Sarepta Therapeutics from $17.00 to $18.00 and gave the stock a “sector perform” rating in a report on Friday, November 6th. Finally, Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research report on Monday, September 28th. Six analysts have rated the stock with a Buy rating, six have given a Hold rating and six have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $23.67.

About Sarepta Therapeutics

Sarepta Therapeutics is a biotechnology company focused on developing genetic medicines for rare diseases, with an emphasis on Duchenne muscular dystrophy (DMD). Its research includes RNA-based treatments designed to affect how genetic instructions are processed, as well as gene therapy approaches. The company’s DMD medicines include exon-skipping therapies such as eteplirsen (Exondys 51), golodirsen (Vyondys 53) and casimersen (Amondys 45). Each is intended for patients with a specific genetic mutation and works by helping cells produce a shortened form of dystrophin, a protein affected by DMD.